CD34
Natural killer cells
cancer immunotherapy
gemcitabine
ovarian cancer
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
7
10
2021
pubmed:
8
10
2021
medline:
16
10
2021
Statut:
epublish
Résumé
Combining natural killer (NK) cell adoptive transfer with tumor-sensitizing chemotherapy is an attractive approach against recurrent ovarian cancer (OC), as OC is sensitive to NK cell-mediated immunity. Previously, we showed that CD34
Identifiants
pubmed: 34616589
doi: 10.1080/2162402X.2021.1981049
pii: 1981049
pmc: PMC8489932
doi:
Substances chimiques
IL2RG protein, human
0
Il2rg protein, mouse
0
Interleukin Receptor Common gamma Subunit
0
Deoxycytidine
0W860991D6
Gemcitabine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1981049Informations de copyright
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
None of the authors have any competing interests.
Références
Oncoimmunology. 2017 May 11;6(8):e1320630
pubmed: 28919991
Gynecol Oncol. 2008 Jan;108(1):166-72
pubmed: 17950450
Crit Rev Oncol Hematol. 2003 Oct;48(1):81-8
pubmed: 14585485
Int J Cancer. 2005 May 10;114(6):1002-9
pubmed: 15645422
Bioconjug Chem. 2013 Jul 17;24(7):1161-73
pubmed: 23758084
Oncoimmunology. 2018 Feb 8;7(5):e1424671
pubmed: 29721384
Cancer Chemother Rep. 1966 May;50(4):219-44
pubmed: 4957125
Gastroenterology. 2016 Aug;151(2):338-350.e7
pubmed: 27210037
Cancer Res. 2006 Jun 15;66(12):6387-94
pubmed: 16778217
PLoS One. 2011;6(6):e20740
pubmed: 21698239
Stem Cells Dev. 2015 Dec 15;24(24):2886-98
pubmed: 26414401
Carbohydr Polym. 2017 Oct 1;173:360-371
pubmed: 28732877
Cancer Chemother Pharmacol. 1996;38(4):335-42
pubmed: 8674156
Drug Metab Rev. 2009;41(2):77-88
pubmed: 19514966
Cancer Immunol Immunother. 2021 May;70(5):1305-1321
pubmed: 33140189
PLoS One. 2013 Jun 05;8(6):e64384
pubmed: 23755121
Sci Rep. 2019 Feb 7;9(1):1544
pubmed: 30733494
PLoS One. 2010 Feb 15;5(2):e9221
pubmed: 20169160
Clin Exp Med. 2017 Feb;17(1):19-31
pubmed: 26449615
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Mol Pharm. 2017 Sep 5;14(9):3121-3133
pubmed: 28719220
J Ovarian Res. 2014 Apr 09;7:38
pubmed: 24713296
Anticancer Res. 2011 Jul;31(7):2505-10
pubmed: 21873167
Gene Ther. 2005 Aug;12(15):1198-205
pubmed: 15800658
J Sep Sci. 2007 Aug;30(12):1811-20
pubmed: 17638352
Breast Cancer Res Treat. 2001 Jul;68(2):171-9
pubmed: 11688520
Gynecol Oncol. 2017 Jun;145(3):453-461
pubmed: 28236454
J Pharmacol Exp Ther. 2017 Mar;360(3):445-456
pubmed: 28028124
Oncoimmunology. 2015 Apr 1;4(7):e1017701
pubmed: 26140247
Int J Gynecol Cancer. 2006 Jan-Feb;16(1):222-30
pubmed: 16445637
Womens Health (Lond). 2007 May;3(3):279-90
pubmed: 19803986
PLoS One. 2015 Oct 06;10(10):e0139809
pubmed: 26439264
Mol Pharm. 2017 May 1;14(5):1365-1372
pubmed: 27798825
Front Immunol. 2021 Jan 28;11:609490
pubmed: 33584686
Int J Gynecol Cancer. 2007 Jan-Feb;17(1):21-31
pubmed: 17291227
PLoS One. 2014 Sep 17;9(9):e103988
pubmed: 25230021
J Clin Oncol. 1999 Jul;17(7):2190-7
pubmed: 10561275
Mol Cancer Ther. 2007 Feb;6(2):644-54
pubmed: 17308061
Cancer Chemother Pharmacol. 2016 Jul;78(1):1-12
pubmed: 27007129
Cancer Immunol Immunother. 2009 May;58(5):641-52
pubmed: 18791713